The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Small Molecule T315 Promotes Casitas B-Lineage Lymphoma–Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation

(2016) Kuo-Yen Huang et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells

(2015) Zhiyun Yu et al.   CANCER LETTERS

Molecular histology of lung cancer: From targets to treatments

(2015) Steven L. Wood et al.   CANCER TREATMENT REVIEWS

Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235

(2015) C. P. Hall et al.   CLINICAL CANCER RESEARCH

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors

(2015) Michael Juchum et al.   DRUG RESISTANCE UPDATES

Signal Transduction in Cancer

(2015) R. Sever et al.   Cold Spring Harbor Perspectives in Medicine

PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer

(2014) HaiXia Li et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced

(2014) Abdelghani Jebahi et al.   CANCER LETTERS

The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance

(2014) Oscar Tapia et al.   VIRCHOWS ARCHIV

PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways

(2014) L Chang et al.   Cell Death & Disease

Targeting PI3K/Akt/mTOR Signaling in Cancer

(2014) Camillo Porta et al.   Frontiers in Oncology

Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

(2013) Carlos Rodrigo Gil del Alcazar et al.   CLINICAL CANCER RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance ofepidermal growth factor receptormutant lung cancer cells triggered by hepatocyte growth factor

(2013) Takako Sano et al.   INTERNATIONAL JOURNAL OF CANCER

Coexistent mutations ofKRASandPIK3CAaffect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer

(2013) Areumnuri Kim et al.   INTERNATIONAL JOURNAL OF CANCER

Trifluoperazine, an Antipsychotic Agent, Inhibits Cancer Stem Cell Growth and Overcomes Drug Resistance of Lung Cancer

(2012) Chi-Tai Yeh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

(2011) C. Santiskulvong et al.   CLINICAL CANCER RESEARCH

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

(2011) Luis I Toledo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

The Association of CCND1 Overexpression and Cisplatin Resistance in Testicular Germ Cell Tumors and Other Cancers

(2010) Elodie E. Noel et al.   AMERICAN JOURNAL OF PATHOLOGY

Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

(2010) Tzu-Hua Chang et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas

(2010) A. P. Bhatt et al.   BLOOD

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

(2010) F. Chiarini et al.   CANCER RESEARCH

mTOR signaling and drug development in cancer

(2010) Janet Dancey   Nature Reviews Clinical Oncology

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

The mTOR Inhibitor Rapamycin Suppresses DNA Double-Strand Break Repair

(2010) Honghong Chen et al.   RADIATION RESEARCH

Relationship of Deregulated Signaling Converging onto mTOR with Prognosis and Classification of Lung Adenocarcinoma Shown by Two Independent In silico Analyses

(2009) H. Ebi et al.   CANCER RESEARCH

Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations

(2009) G. Konstantinidou et al.   CANCER RESEARCH

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

(2009) Saskia M. Brachmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

GSK-3β-dependent destabilization of cyclin D1 mediates replicational stress-induced arrest of cell cycle

(2008) Atish Mukherji et al.   FEBS LETTERS

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

DNA Damage Response Pathways in Tumor Suppression and Cancer Treatment

(2008) Yulong Liang et al.   WORLD JOURNAL OF SURGERY